Preformulation & Formulation Development
Formulation development underpinned by biopharmaceutics & clinical knowledge
Quotient Sciences has more than 30 years of experience developing a breadth of formulations for small molecules and peptides, across a range of indications. With expertise in simple and complex dosage forms, we have formulated over 1,500 molecules. Our unique track record in clinical research, means we know what it takes to develop formulations across the full development pathway from preclinical to late stage.
From fit-for-purpose preclinical and first-in-human (FIH) dosage forms to optimized drug products for late-stage development and market, we work with you to develop the most appropriate formulation based on the physicochemical and biopharmaceutics properties of your molecule.
Operating from our state-of-the-art facilities in the U.S. and U.K. and with a global team of over 200 formulation and analytical scientists, we offer you a comprehensive and tailored formulation development service.
A breadth of formulation capabilities
-
Formulation DesignAccess formulation design expertise in a variety of drug product formats.
-
Preformulation ScreeningAccess our characterization techniques that speed your molecules development
-
First-In-HumanHow do I select the most appropriate first-in-human formulation?
-
Solubility EnhancementOvercome solubility challenges with your molecule
-
Inhaled Drug Product DevelopmentDeveloping an inhaled drug product?
-
Modified ReleaseOptimize your modified-release formulations
-
Analytical ServicesHow do I ensure the performance of my drug product?
-
Gamma Scintigraphy ImagingHow do I design and conduct my scintigraphic studies?
-
Pediatric DevelopmentCustomized pediatric solutions
-
Spray DryingImproving the bioavailability of poorly soluble compounds
-
Case StudiesDCS classification of NCE - Case studyUS Biotech wanted to determine the DCS (Developability Classification System) designation for their small molecule. This included project scope and outcomes of the project.
-
WhitepaperStrategies for Accelerating the Development of Modified Release Oral FormsMR drug delivery can also have commercial benefits and is prevalent as part of product life-cycle management (LCM). Modest reformulation of an already approved drug from an IR to MR format allows both line and patent extension opportunities and continued market exclusivity.
-
Info SheetPBPK Modelling & SimulationQuotient Sciences is a leading expert in the application of physiologically based pharmacokinetic (PBPK) modelling and simulation (M&S) science to drug development.
-
Info SheetFormulation DevelopmentFrom preclinical and first-in-human (FIH) dosage forms to optimization of your drug products for late stage development, we work with you to develop the most appropriate formulation.